Impax releases generic version of dutasteride capsules, 0.5 mg

Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that on November 20, the Company's development and manufacturing partner received final approval by the U.S. Food and Drug Administration for a generic version of dutasteride capsules, 0.5 mg. The Company immediately initiated commercialization activities through its generic division. This is the 13th generic product launched in 2015 by Impax's generic division.

According to IMS Health (NSP), U.S. brand and generic sales of dutasteride capsules, 0.5 mg were approximately $457 million for the 12 months ending in September 2015.


Impax Laboratories, Inc.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
Active compound in Lion’s Mane mushroom improves nerve growth and memory